Comparative effectiveness of infliximab and adalimumab for Crohn's disease
Clinical Gastroenterology and Hepatology , 04/21/2014Osterman MT, et al.
This study compared the effectiveness of infliximab and adalimumab, the 2 most commonly used anti–tumor necrosis factor agents, in patients with Crohn's disease (CD). The authors observed similar effectiveness of infliximab and adalimumab for CD on the basis of 3 clinically important outcome measures.
The authors conducted a retrospective cohort study by using U.S. Medicare data from 2006 through 2010.
Patients with CD who were new users of infliximab (n = 1459) or adalimumab (n = 871) after January 31, 2007, were included.
Patients older than age 85 and those with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis were excluded.
The primary outcome measures were disease persistence on therapy at week 26, surgery (including bowel resection, creation of an ostomy, or surgical treatment of a perforation or abscess), and hospitalization for CD.
Propensity score-adjusted logistic and Cox regression were used to compute adjusted odds ratios or hazard ratios and 95% confidence intervals (CIs).
After 26 weeks of treatment, 49% of patients receiving infliximab remained on drug, compared with 47% of those receiving adalimumab (odds ratio, 0.98; 95% CI, 0.81–1.19).
Fewer patients treated with infliximab underwent surgery than those treated with adalimumab, but this difference was not statistically significant (5.5 vs 6.9 surgeries per 100 person-years; hazard ratio, 0.79; 95% CI, 0.60–1.05).
Rates of hospitalization did not differ between groups (hazard ratio, 0.88; 95% CI, 0.72–1.07).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.